subsidiary

KMPJM will provide diagnostic and prognostic testing services based on genes, proteins, and other molecules to aid physicians in assessing and treating patients.

The Australian company incorporated the subsidiary as it plans for the US launch of its ResistancePlus MG assay.

The Singapore-based firm has established a US subsidiary and named distributors to sell its products across Europe, the Middle East, and Asia.

Sweden-based Immunovia is preparing to launch its first diagnostic — a liquid biopsy test for pancreatic cancer — in 2018.

The subsidiary, called ExcitePCR, will own and complete development of the company's Firefly Dx real-time PCR breadboard prototype pathogen detection system.

The subsidiary is being formed in support of Biocartis' recent US distribution deal with Thermo Fisher Scientific.

Ardigen will form a new business unit to conduct biological and clinical data analysis in genomics, transcriptomics, proteomics, metabolomics, and immunomics.

The firm says a direct presence in China will help it expand its reach into a market where it has already sold 60 MassArray systems.

The Geneva-based subsidiary was opened to respond to increasing European demand for the firm's LinkSeq tissue typing test.

The South Korean molecular diagnostics firm plans to grow its global market presence and pursue FDA approval for its products from Seegene Technologies, its new base in California.

Pages

Customers might want to consider what they might learn about their risk of diseases like Alzheimer's before snagging the genetic testing kits that are on many gift guides this year, NJ.com writes.

The Wall Street Journal reports there is uncertainty surrounding whether He Jiankui's embryo editing did what he said it did.

Stat News reports that the pause on procuring fetal tissue for intramural US National Institutes of Health research will soon affect additional labs there.

In Nature this week: genomic analysis of the invasive fall webworm, amp of constrained coding regions within the human genome, and more.